Technology

Physiatrist DJ Kennedy, MD, is excited by the potential for new, and even existing technology, to present novel options for diagnosis, monitoring, and treatment.

Your daily dose of clinical news you may have missed.

Try this 7-question quiz on the 2023 guidelines from The Endocrine Society that focus on advances in diabetes treatment that help minimize risk of hypoglycemia.

Mean time in range increased by ~10% and time above range decreased by 8.1% in study participants taking as few as a single antihyperglycemic medication.

Prescriptions for continuous glucose monitoring for patients with T2D are increasing, a new study finds, and the authors report on characteristics of new CGM users.

Your daily dose of clinical news you may have missed.

Findings from new study demonstrate the potential benefits of continuing telehealth services and medications for opioid use disorder.

Your daily dose of clinical news you may have missed.

An Apple Watch feature designed to detect atrial fibrillation was associated with a low rate of false-positive detections and high specificity in persons with AF.

Your daily dose of clinical news you may have missed.

ACC 2023. Electronic nudges highlighting the potential cardiovascular benefits of flu vaccination led to a modest uptake in vaccination rates among older adults in Denmark, according to results of the NUDGE-FLU trial.

The prescription remote electrical neuromodulation device is now cleared for both acute and preventive treatment of migraine in those aged ≥12 years, according to Theranica.

ACC 2023. New study found cognitive behavioral therapy delivered via mobile app significantly reduced HbA1c and need for antihyperglycemic intensification compared to use of a control app.

An EHR prompt to a physician alone or in combination with a previsit patient prompt both increased statin prescribing in primary care but a patient prompt alone did not.

Wearable activity trackers could potentially support clinical care for patients with pulmonary arterial hypertension, according to a new study.

AHA 2022: An estimated 18% of Americans with heart disease reported using wearables, compared with 29% of the total US population.

A discussion with Lynn Webster, MD, about the importance and future of mobile health technology for chronic pain management.

Telehealth continues to support continuity of care and to increase access to and willingness to use the health care system, according to survey authors.

Blood pressure reduction of approximately 11 mm Hg was seen at 6 months regardless of device used, suggesting patients can keep SMBP simple.

Screening for atrial fibrillation with 6 wrist-worn wearable devices proved more cost effective than no screening and had greater relative benefit than using traditional modalities.

Use of wearable activity trackers increased daily time spent walking by 40 minutes and was linked to a 2-lb weight loss across age groups and populations.

A free, automated online behavioral weight loss program led to a mean 5% reduction in weight over 12 weeks without clinician involvement, a new study reports.

The cloud-based machine learning algorithm allows the stethoscope to identify and differentiate between innocent and structural murmurs that may signal valve disease.

Called SMART WARS, a new study assessed diagnostic utility of the 2 wearable devices in older adults and considered combined device/clinician interpretation of ECG readings.

Characteristics associated with discussions of wearable devices during primary care visits include female sex, higher income, and obesity, showed new study.

Apple recently announced a new software release that will allow Apple Watch users access to health care-focused features and apps.

ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.

ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.

ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.